11/25
01:54 pm
nerv
Minerva Neurosciences (NASDAQ:NERV) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
Low
Report
Minerva Neurosciences (NASDAQ:NERV) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
11/19
08:30 am
nerv
Minerva Neurosciences Appoints Dr. Inderjit Kaul to the Company’s Board of Directors
Low
Report
Minerva Neurosciences Appoints Dr. Inderjit Kaul to the Company’s Board of Directors
11/18
01:18 pm
nerv
Minerva Neurosciences (NASDAQ:NERV) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
Low
Report
Minerva Neurosciences (NASDAQ:NERV) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
11/6
08:10 am
nerv
Minerva Neurosciences (NASDAQ:NERV) had its price target lowered by analysts at HC Wainwright from $5.00 to $4.00. They now have a "neutral" rating on the stock.
Low
Report
Minerva Neurosciences (NASDAQ:NERV) had its price target lowered by analysts at HC Wainwright from $5.00 to $4.00. They now have a "neutral" rating on the stock.
11/5
07:42 am
nerv
Minerva Neurosciences Reports Third Quarter 2025 Financial Results and Business Updates [Yahoo! Finance]
Low
Report
Minerva Neurosciences Reports Third Quarter 2025 Financial Results and Business Updates [Yahoo! Finance]
11/5
07:30 am
nerv
Minerva Neurosciences Reports Third Quarter 2025 Financial Results and Business Updates
Medium
Report
Minerva Neurosciences Reports Third Quarter 2025 Financial Results and Business Updates
10/25
12:09 pm
nerv
Minerva Neurosciences (NASDAQ:NERV) had its "sell (d+)" rating reaffirmed by analysts at
Weiss Ratings.
Low
Report
Minerva Neurosciences (NASDAQ:NERV) had its "sell (d+)" rating reaffirmed by analysts at
Weiss Ratings.
10/21
08:00 am
nerv
Minerva Neurosciences Announces Financing of up to $200 Million to Advance Roluperidone for the Treatment of Negative Symptoms in Patients with Schizophrenia Through a Phase 3 Confirmatory Trial and Resubmission of its New Drug Application and Preparation
High
Report
Minerva Neurosciences Announces Financing of up to $200 Million to Advance Roluperidone for the Treatment of Negative Symptoms in Patients with Schizophrenia Through a Phase 3 Confirmatory Trial and Resubmission of its New Drug Application and Preparation